E. Anders Kolb: Blood Cancer United Preserves Access to Luveltamab Tazevibulin for Children with AML
oncodaily - E. Anders Kolb, Chief Executive Officer of Blood Cancer United, shared a post on LinkedIn: “Today we announced a first‑of‑its‑kind intervention from a nonprofit. Blood Cancer United has stepped up […]
AI Summary: A nonprofit stepped into a supply crisis and purchased the remaining stock of an experimental agent to preserve access for children with acute myeloid leukemia. The emergency buy protects current patients from treatment interruption while stakeholders scramble for a durable manufacturing or regulatory fix, illustrating how charities sometimes act like pharma’s safety net.
Related Stories
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 7 wks
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 7 wks
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 1 month
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 2 months
Romiplostim reduces chemotherapy‑induced thrombocytopenia and prevents recurrence / 2 months
Neoadjuvant GOLP improves event‑free survival in high‑risk intrahepatic cholangiocarcinoma / 2 months
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 10 days
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Food Safety, Digital Health, Drug Development, Vitamin D and look for the RSS link.
StackHealth Time Machine